Skip to main content

Market Overview

Adamis Pharma Stock Gains On Resubmission Of Zimhi US Application For Opioid Overdose

Share:
Adamis Pharma Stock Gains On Resubmission Of Zimhi US Application For Opioid Overdose
  • Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) has resubmitted a marketing application to the FDA for Zimhi, a naloxone injection product candidate intended to treat opioid overdose.
  • "Based on FDA feedback received during our Type A meeting in April, we have resubmitted our NDA for ZIMHI, which I am confident fully addresses the issues raised in the Complete Response Letter," said President and CEO Dr. Dennis J. Carlo.
  • In November last year, the company received a CRL. The FDA questions were generally related to new Chemistry, Manufacturing, and Controls issues.
  • Price Action: ADMP shares are trading 4.02% higher at $0.74 on the last check Monday.
 

Related Articles (ADMP)

View Comments and Join the Discussion!

Posted-In: Briefs OpioidsBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com